Skip to main content

Table 2 Primary and secondary outcomes

From: Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial

Primary outcome

Secondary outcomes

HPR (PR ≥ 240 units)

Death from cardiovascular cause

 

Myocardial infarction

 

Stent thrombosis

 

Hemorrhagic or non-hemorrhagic stroke

 

Target vessel revascularization

 

Bleeding event defined by Thrombolysis in Myocardial Infarction (TIMI) criteria and BARC

  1. HPR, high platelet reactivity: more than 240 units determined via VerifyNow (Accumetrics, San Diego, CA, USA); PR, platelet reactivity; BARC, bleeding academic research consortium.
Back to article page

Trials

ISSN: 1745-6215